Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:52:119-155.
doi: 10.1007/7854_2020_187.

GABAB Receptors and Drug Addiction: Psychostimulants and Other Drugs of Abuse

Xiaofan Li  1 , Paul A Slesinger  2
Affiliations

GABAB Receptors and Drug Addiction: Psychostimulants and Other Drugs of Abuse

Xiaofan Li et al. Curr Top Behav Neurosci. 2022.

Abstract

Metabotropic GABAB receptors (GABABRs) mediate slow inhibition and modulate synaptic plasticity throughout the brain. Dysfunction of GABABRs has been associated with psychiatric illnesses and addiction. Drugs of abuse alter GABAB receptor (GABABR) signaling in multiple brain regions, which partly contributes to the development of drug addiction. Recently, GABABR ligands and positive allosteric modulators (PAMs) have been shown to attenuate the initial rewarding effect of addictive substances, inhibit seeking and taking of these drugs, and in some cases, ameliorate drug withdrawal symptoms. The majority of the anti-addiction effects seen with GABABR modulation can be localized to ventral tegmental area (VTA) dopamine neurons, which receive complex inhibitory and excitatory inputs that are modified by drugs of abuse. Preclinical research suggests that GABABR PAMs are emerging as promising candidates for the treatment of drug addiction. Clinical studies on drug dependence have shown positive results with GABABR ligands but more are needed, and compounds with better pharmacokinetics and fewer side effects are critically needed.

Keywords: Dopamine; Positive allosteric modulators (PAMs); Synaptic plasticity; Ventral tegmental area (VTA).

PubMed Disclaimer

References

    1. Agabio R, Colombo G (2015) GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators. Psychiatr Pol 49(2):215–223 - PubMed
    1. Ahmadi-Abhari SA, Akhondzadeh S, Assadi SM, Shabestari OL, Farzanehgan ZM, Kamlipour A (2001) Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial. J Clin Pharm Ther 26(1):67–71 - PubMed
    1. Akhondzadeh S, Ahmadi-Abhari SA, Assadi SM, Shabestari OL, Kashani AR, Farzanehgan ZM (2000) Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. J Clin Pharm Ther 25(5):347–353 - PubMed
    1. Amantea D, Bowery NG (2004) Reduced inhibitory action of a GABAB receptor agonist on [3H]-dopamine release from rat ventral tegmental area in vitro after chronic nicotine administration. BMC Pharmacol 4:24 - PubMed - PMC
    1. Amantea D, Tessari M, Bowery NG (2004) Reduced G-protein coupling to the GABAB receptor in the nucleus accumbens and the medial prefrontal cortex of the rat after chronic treatment with nicotine. Neurosci Lett 355(3):161–164 - PubMed

MeSH terms